Literature DB >> 7635182

Monocyte chemoattractant protein-1 stimulates tumor necrosis and recruitment of macrophages into tumors in tumor-bearing nude mice: increased granulocyte and macrophage progenitors in murine bone marrow.

Y Hoshino1, K Hatake, T Kasahara, Y Takahashi, M Ikeda, H Tomizuka, T Ohtsuki, M Uwai, N Mukaida, K Matsushima.   

Abstract

Monocyte chemoattractant protein-1 (MCP-1) belongs to the newly recognized "chemokine" superfamily of activation-inducible cytokines. We report here that MCP-1 gene-transferred mouse myeloma cells modulate tumor necrosis in myeloma-bearing nude mice. We established an MCP-1-producing myeloma cell line (X63-MCP-1) by transfection with human MCP-1 cDNA as well as interleukin-8-producing X63 cells (X63 IL-8). Each cell line showed the same growth characteristics in vitro, and 1 x 10(7) cells per mouse were injected into the peritoneal cavity resulting in the formation of tumors. Hematologic studies, including peripheral white blood cell counts and differentiation, showed no differences among the groups. They formed tumors in the same manner, which we observed from weeks 2.5 to 9. MCP-1 mice showed more tumor necrosis and infiltration of the macrophages into the tissue surrounding the tumor. In situ hybridization, using a partial cDNA as a probe, showed that macrophages contained MCP-1 mRNA. Bone marrow cell colony-forming assay showed a greater number of both granulocyte and macrophage colonies in MCP-1 mouse femur than in those of controls or interleukin-8 mice. MCP-1 has no direct stimulatory activity on stem cells, but longer exposure to MCP-1 in vivo might stimulate both granulocyte and macrophage progenitors and recruitment of macrophages into tumors, and it might explain the antitumor activity of macrophages in tumor-bearing nude mice.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7635182

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  7 in total

1.  Chemokine signaling in cancer: Implications on the tumor microenvironment and therapeutic targeting.

Authors:  Stacey L Hembruff; Nikki Cheng
Journal:  Cancer Ther       Date:  2009-04-14

2.  In vivo expression of the novel CXC chemokine BRAK in normal and cancerous human tissue.

Authors:  M J Frederick; Y Henderson; X Xu; M T Deavers; A A Sahin; H Wu; D E Lewis; A K El-Naggar; G L Clayman
Journal:  Am J Pathol       Date:  2000-06       Impact factor: 4.307

3.  CCL2/CCR2 chemokine signaling coordinates survival and motility of breast cancer cells through Smad3 protein- and p42/44 mitogen-activated protein kinase (MAPK)-dependent mechanisms.

Authors:  Wei Bin Fang; Iman Jokar; An Zou; Diana Lambert; Prasanthi Dendukuri; Nikki Cheng
Journal:  J Biol Chem       Date:  2012-08-27       Impact factor: 5.157

4.  Thrombospondin 1 promotes tumor macrophage recruitment and enhances tumor cell cytotoxicity of differentiated U937 cells.

Authors:  Gema Martin-Manso; Susana Galli; Lisa A Ridnour; Maria Tsokos; David A Wink; David D Roberts
Journal:  Cancer Res       Date:  2008-09-01       Impact factor: 12.701

5.  Lipophilicity of Bacteriochlorin-Based Photosensitizers as a Determinant for PDT Optimization through the Modulation of the Inflammatory Mediators.

Authors:  Barbara Pucelik; Luis G Arnaut; Janusz M Dąbrowski
Journal:  J Clin Med       Date:  2019-12-19       Impact factor: 4.241

6.  The inhibitory effects of butein on cell proliferation and TNF-α-induced CCL2 release in racially different triple negative breast cancer cells.

Authors:  Patricia Mendonca; Ainsley Horton; David Bauer; Samia Messeha; Karam F A Soliman
Journal:  PLoS One       Date:  2019-10-30       Impact factor: 3.240

7.  Chemokine receptor CCR2 is expressed by human multiple myeloma cells and mediates migration to bone marrow stromal cell-produced monocyte chemotactic proteins MCP-1, -2 and -3.

Authors:  I Vande Broek; K Asosingh; K Vanderkerken; N Straetmans; B Van Camp; I Van Riet
Journal:  Br J Cancer       Date:  2003-03-24       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.